Abstract
Triple-negative breast cancer (TNBC) has a very high rate of recurrence and till now there is no standard of care. Because of the sensitivity of TNBC to platinum compounds and the synergistic effect between bevacizumab and paclitaxel according to many studies, our aim was to combine all these agents to evaluate the efficacy of bevacizumab in combination with carboplatin and paclitaxel as first-line treatment in metastatic TNBC (mTNBC) and to predict whom can benefit from this combination.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
